100 results
8-K
EX-10.1
BPMC
Blueprint Medicines Corp
3 Jul 19
Entry into a Material Definitive Agreement
4:15pm
([***]), and the screening and validation phase of Part 2 [***] shall end as follows: [***].”
2. The definition of “Leftover Targets” in Section 1.73 … of the Agreement shall be amended by deleting it in its entirety and replacing it with the following Section 1.73:
“1.73 Leftover Targets
The term
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
16 Oct 19
Entry into a Material Definitive Agreement
6:51am
and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown … could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
28 Feb 22
Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
8:26am
will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. As a core part … new ways to treat difficult to drug and novel targets, as well as address on-target resistance mechanisms. This collaboration with Proteovant
8-K
EX-99.2
BPMC
Blueprint Medicines Corp
1 Oct 18
Regulation FD Disclosure
12:00am
% of FOP patients 85% – 97% are ALK2R206H ALK2R206H mice recapitulate all the key features of FOP Selective ALK2 inhibition targets the underlying cause … * * * “Anti-targets” * * * * * * * * * 9 Data on file. Blueprint Medicines Corporation 2018 Non-selective Selective Selective
Structure-based drug
8-K
EX-10.1
BPMC
Blueprint Medicines Corp
28 Jul 21
Other Events
4:15pm
Development Costs
Development Plan
Effective Date
EU
Excluded Field
Excluded Targets
Expert
Exploit
FBMC
FDA
FDCA
Field
Filing
First Commercial Sale …
JOT
JRC
Know-How
Lead Nomination
Lead Optimization
Lead Series Identified Criteria
Leftover Targets
Library Compound
Licensed Product
Major Countries
8-K
EX-99.1
jthgk75s
25 Apr 24
Other Events
8:30am
8-K
EX-99.1
3w66i jbnqai
7 Jan 19
Regulation FD Disclosure
8:00am
8-K
EX-99.2
os2ivufsab
8 Jan 24
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
8:03am
10-K
EX-10.15
98lnk6lfx lvpru
11 Mar 16
Annual report
12:00am
8-K
EX-99.1
051d040pb10 wix5suxr
13 Jan 20
Regulation FD Disclosure
8:30am
8-K
EX-99.3
updx28 80zj
9 Dec 19
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib
7:31am
8-K
EX-99.1
qf70pz
4 Jun 19
Regulation FD Disclosure
7:30am
10-K
sqkh1hx 0hpjetewz
11 Mar 16
Annual report
12:00am